150 related articles for article (PubMed ID: 2198122)
61. Genetic syndromic immunodeficiencies with antibody defects.
Ming JE; Stiehm ER
Immunol Allergy Clin North Am; 2008 Nov; 28(4):715-36, vii. PubMed ID: 18940571
[TBL] [Abstract][Full Text] [Related]
62. Consensus conference. Conference on intravenous immunoglobulin. National Institutes of Health.
Conn Med; 1990 Dec; 54(12):677-83. PubMed ID: 2282801
[No Abstract] [Full Text] [Related]
63. Further fears of HIV in India.
Jayaraman KS
Nature; 1989 Feb; 337(6207):496. PubMed ID: 2536899
[No Abstract] [Full Text] [Related]
64. Intravenous immune globulin and the compromised host. Proceedings of a symposium, September 2l to 23, 1983, Dallas.
Am J Med; 1984 Mar; 76(3A):1-231. PubMed ID: 6201066
[No Abstract] [Full Text] [Related]
65. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
[TBL] [Abstract][Full Text] [Related]
66. Intramuscular versus intravenous immunoglobulin replacement therapy and measurement of immunoglobulin levels during immunoglobulin replacement therapy.
Lieberman P; Berger M
J Allergy Clin Immunol Pract; 2013; 1(6):705-6. PubMed ID: 24565727
[No Abstract] [Full Text] [Related]
67. A new subcutaneous immune globulin (HyQvia) for primary immunodeficiency.
Med Lett Drugs Ther; 2015 Aug; 57(1476):121-2. PubMed ID: 26305523
[No Abstract] [Full Text] [Related]
68. Immunoglobulins: current understanding and future directions.
Jolles S; Jordan SC; Orange JS; van Schaik IN
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):163-8. PubMed ID: 25546806
[No Abstract] [Full Text] [Related]
69. [Application of immunoglobulins in practice].
Weber-Oldecop H
ZFA (Stuttgart); 1981 Jan; 57(3):169-76. PubMed ID: 7210836
[No Abstract] [Full Text] [Related]
70. Restoration of suppressor T-cell functions in children with AIDS following intravenous gamma globulin treatment.
Gupta A; Novick BE; Rubinstein A
Am J Dis Child; 1986 Feb; 140(2):143-6. PubMed ID: 2936236
[TBL] [Abstract][Full Text] [Related]
71. The clinical use of intravenous immunoglobulin in pediatrics.
Wahn V
Indian J Pediatr; 1987; 54(5):641-53. PubMed ID: 3428982
[No Abstract] [Full Text] [Related]
72. Gamma globulin therapy.
South MA
Cutis; 1978 Oct; 22(4):411, 428-9. PubMed ID: 699629
[No Abstract] [Full Text] [Related]
73. [Immunoglobulins in primary antibody deficiency: should they also be used in sepsis and other indications?].
Kluge S; de Heer G; Nierhaus A; Kreymann G
Internist (Berl); 2007 Nov; 48(11):1297-302, 1304. PubMed ID: 17901939
[TBL] [Abstract][Full Text] [Related]
74. Polyvalent immune globulin usage by indication in the United States, 2012: a quantitative analysis of the use of polyvalent immune globulin (intravenous and subcutaneous) by medical indication in the United States in 2012.
Robert P; Hotchko M
Transfusion; 2015 Jul; 55 Suppl 2():S6-12. PubMed ID: 26174899
[No Abstract] [Full Text] [Related]
75. Clinical uses of intravenous immunoglobulins.
Berkman SA; Lee ML; Gale RP
Ann Intern Med; 1990 Feb; 112(4):278-92. PubMed ID: 2404449
[TBL] [Abstract][Full Text] [Related]
76. Immune globulin solubility in 5% dextrose injection.
Donnelly RF
Am J Hosp Pharm; 1990 Sep; 47(9):1976. PubMed ID: 2121027
[No Abstract] [Full Text] [Related]
77. Positive immunohematologic and serologic test results due to high-dose intravenous immune globulin administration.
Garcia L; Huh YO; Fischer HE; Lichtiger B
Transfusion; 1987; 27(6):503. PubMed ID: 3318029
[No Abstract] [Full Text] [Related]
78. Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.
Ballow M; Wasserman RL; Jolles S; Chapel H; Berger M; Misbah SA
J Clin Immunol; 2017 Aug; 37(6):517-518. PubMed ID: 28695366
[No Abstract] [Full Text] [Related]
79. Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".
Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
J Clin Immunol; 2017 Nov; 37(8):739-740. PubMed ID: 28875256
[No Abstract] [Full Text] [Related]
80. Companies cooperate in emergency supply program for IGIV.
Landis NT
Am J Health Syst Pharm; 1999 Apr; 56(7):599. PubMed ID: 10423201
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
